一名患有嗜酸性食管炎和过敏性哮喘的成年患者对度普利尤单抗的快速反应。
Rapid response to dupilumab in an adult patient with eosinophilic esophagitis and allergic asthma.
作者信息
Klein Benjamin, Treudler Regina
机构信息
Leipzig Comprehensive Allergy Center LICA-CAC, Department of Dermatology, Venereology and Allergology, University of Leipzig, Leipzig, Germany.
Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, and.
出版信息
Allergol Select. 2024 Apr 5;8:78-81. doi: 10.5414/ALX02485E. eCollection 2024.
BACKGROUND
Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus that belongs to the spectrum of Th2-mediated diseases. It is often associated with atopic comorbidities such as allergic asthma (AA) and poses a therapeutic challenge.
CASE REPORT
We report on a 43-year-old patient with EoE and AA who did not show sufficient therapeutic control despite standard therapy. We started treatment with dupilumab, whereupon both EoE and AA rapidly improved and complete symptom resolution could be documented. The response to dupilumab was assessed by laboratory monitoring and gastroscopy, which showed a reduction of markers of type II inflammation and eosinophilic infiltrates in the esophagus.
SUMMARY
Our report emphasizes the effective and safe use of dupilumab as a treatment option for EoE with concomitant beneficial effects on AA.
背景
嗜酸性食管炎（EoE）是一种食管炎症性疾病，属于Th2介导的疾病谱。它常与过敏性哮喘（AA）等特应性合并症相关，带来治疗挑战。
病例报告
我们报告了一名43岁患有EoE和AA的患者，尽管接受了标准治疗，但治疗控制效果不佳。我们开始使用度普利尤单抗进行治疗，随后EoE和AA均迅速改善，且可记录到症状完全缓解。通过实验室监测和胃镜检查评估了对度普利尤单抗的反应，结果显示食管中II型炎症标志物和嗜酸性粒细胞浸润减少。
总结
我们的报告强调了度普利尤单抗作为EoE治疗选择的有效性和安全性，同时对AA有有益作用。
Zotero 插件